Skip to content
approvedSexual Health

Ganirelix

Also known as: Antagon, Orgalutran, Ganirelix Acetate, RS-26306

Ganirelix is a synthetic decapeptide GnRH antagonist approved by the FDA for the prevention of premature luteinizing hormone (LH) surges during controlled ovarian hyperstimulation in IVF (in vitro fertilization) procedures. Unlike GnRH agonists that cause initial stimulation before suppression, ganirelix provides immediate, dose-dependent suppression of LH and FSH by competitive blockade of GnRH receptors on pituitary gonadotrophs, allowing more precise control of ovulation timing.

3 cited references·5 researched benefits

Quick Answer

Ganirelix (Antagon/Orgalutran) is an FDA-approved synthetic GnRH antagonist used in IVF protocols to prevent premature ovulation during controlled ovarian stimulation. It works by immediately and competitively blocking GnRH receptors on the pituitary gland, suppressing LH and FSH release without the initial flare effect of GnRH agonists. Ganirelix is administered as a daily subcutaneous injection, typically starting on day 5-6 of ovarian stimulation, and has a half-life of approximately 13 hours.

Key Facts

Mechanism
Ganirelix is a synthetic decapeptide that competitively antagonizes the GnRH receptor (GnRHR) on anterior pituitary gonadotroph cells. By occupying the receptor without activating it, ganirelix immediately blocks endogenous GnRH signaling, producing rapid, dose-dependent suppression of both LH and FSH secretion. This prevents the premature LH surge that would trigger ovulation before egg retrieval. Unlike GnRH agonists (which initially stimulate gonadotropin release before desensitizing receptors), ganirelix provides immediate suppression without a flare effect, allowing shorter and more flexible IVF stimulation protocols.
Research Status
approved
Half-Life
~13 hours
Molecular Formula
C₈₀H₁₁₃ClN₁₈O₁₃
Primary Use
Sexual Health
Table of Contents

Benefits

  • Prevents premature LH surge and ovulation during IVF ovarian stimulationstrong
  • Immediate onset — no flare effect unlike GnRH agonist protocolsstrong
  • Shorter treatment duration compared to GnRH agonist long protocolsstrong
  • Reduced risk of ovarian hyperstimulation syndrome (OHSS) compared to agonist protocolsmoderate
  • Allows use of GnRH agonist trigger instead of hCG, further reducing OHSS riskmoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Subcutaneous injection250 mcgOnce dailyStarted on stimulation day 5 or 6 (or when lead follicle reaches 13-14 mm), continued daily until trigger day (hCG or GnRH agonist trigger). Injected in the abdomen or upper thigh.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Injection site reactions (redness, swelling, bruising)common
  • Headachecommon
  • Abdominal pain related to ovarian stimulationcommon
  • Nauseacommon
  • Ovarian hyperstimulation syndrome (OHSS)serious
  • Allergic or anaphylactic reaction (very rare)serious

Frequently Asked Questions

What is the difference between ganirelix and cetrorelix?
Both are GnRH antagonists used in IVF to prevent premature ovulation, and clinical outcomes (pregnancy rates, oocyte yield) are comparable in head-to-head trials. The main differences are pharmacokinetic: ganirelix has a half-life of ~13 hours while cetrorelix has a longer, dose-dependent half-life (5-60 hours). Cetrorelix also offers a single 3 mg depot option that can suppress LH for up to 4 days, while ganirelix is only available as a daily 0.25 mg injection. Choice between them is typically based on physician preference and local availability.
Why use a GnRH antagonist instead of an agonist for IVF?
GnRH antagonist protocols (using ganirelix or cetrorelix) offer several advantages: immediate LH suppression without a 2-3 week desensitization period, shorter overall treatment duration, fewer injections, lower gonadotropin requirements, and significantly reduced risk of ovarian hyperstimulation syndrome. Antagonist protocols also allow the use of a GnRH agonist trigger instead of hCG, which virtually eliminates severe OHSS in high-risk patients. Antagonist protocols have become the standard approach in many IVF clinics worldwide.
When should ganirelix be started during an IVF cycle?
Ganirelix is typically started on stimulation day 5 or 6, or alternatively when the lead follicle reaches 13-14 mm on ultrasound (flexible protocol). It is given as a 0.25 mg daily subcutaneous injection and continued until the trigger injection day. Starting too early can suppress follicular development, while starting too late risks a premature LH surge. The flexible start approach based on follicle size has become the most common protocol.

References

  1. 1
    A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix to prevent premature LH surges in women undergoing ovarian stimulation(2000)PubMed ↗
  2. 2
    GnRH antagonist ganirelix in IVF: a review of clinical trials(2002)PubMed ↗
  3. 3
    GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis(2006)PubMed ↗

Latest Research

Last updated: 2026-02-19